Pacira BioSciences (PCRX) Projected to Release Earnings on Thursday

Pacira BioSciences (NASDAQ:PCRX) is expected to be posting its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect Pacira BioSciences to announce earnings of $0.7320 per share and revenue of $182.87 million for the quarter. Interested persons can check the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Thursday, November 12, 2026 at 4:30 PM ET.

Pacira BioSciences (NASDAQ:PCRX) last issued its quarterly earnings results on Tuesday, August 4th. The company reported $0.73 EPS for the quarter, topping analysts’ consensus estimates of $0.65 by $0.08. Pacira BioSciences had a return on equity of 9.68% and a net margin of 1.96%. The company had revenue of $192.40 million during the quarter, compared to analyst estimates of $191.06 million. During the same period in the previous year, the company earned $0.74 earnings per share. The company’s quarterly revenue was up 6.2% compared to the same quarter last year. On average, analysts expect Pacira BioSciences to post $1.86 EPS for the current fiscal year and $2.37 EPS for the next fiscal year.

Pacira BioSciences Stock Down 0.0%

PCRX opened at $36.39 on Wednesday. The business has a 50 day moving average of $29.53 and a 200-day moving average of $24.96. The stock has a market capitalization of $1.45 billion, a price-to-earnings ratio of 23.33 and a beta of 0.21. The company has a current ratio of 5.04, a quick ratio of 3.94 and a debt-to-equity ratio of 0.54. Pacira BioSciences has a 1-year low of $18.80 and a 1-year high of $36.67.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on the stock. Truist Financial cut shares of Pacira BioSciences from a “buy” rating to a “hold” rating and upped their target price for the company from $31.00 to $36.50 in a research note on Friday, October 9th. Weiss Ratings upgraded shares of Pacira BioSciences from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Thursday, October 8th. Zacks Research downgraded shares of Pacira BioSciences from a “hold” rating to a “strong sell” rating in a report on Monday, October 5th. Needham & Company LLC lowered shares of Pacira BioSciences from a “buy” rating to a “hold” rating in a research report on Thursday, October 8th. Finally, Jefferies Financial Group lowered shares of Pacira BioSciences from a “buy” rating to a “hold” rating and set a $36.00 price objective for the company. in a research report on Thursday, October 8th. One analyst has rated the stock with a Buy rating, nine have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $33.33.

Insider Activity at Pacira BioSciences

In other news, SVP Lauren Riker sold 6,000 shares of the business’s stock in a transaction that occurred on Thursday, October 8th. The stock was sold at an average price of $36.32, for a total transaction of $217,920.00. Following the sale, the senior vice president directly owned 62,284 shares in the company, valued at approximately $2,262,154.88. The trade was a 8.79% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Jonathan Slonin sold 3,040 shares of the company’s stock in a transaction on Monday, August 17th. The shares were sold at an average price of $23.23, for a total value of $70,619.20. Following the completion of the transaction, the insider owned 216,384 shares of the company’s stock, valued at $5,026,600.32. The trade was a 1.39% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.40% of the stock is currently owned by company insiders.

About Pacira BioSciences

Pacira BioSciences, Inc is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain-management and regenerative health solutions. The company’s products are designed to address acute postsurgical pain and osteoarthritis-related pain while supporting efforts to reduce reliance on opioid medications.

Pacira’s lead product is EXPAREL, an extended-release formulation of bupivacaine administered by injection for postsurgical pain management. The company also markets ZILRETTA, an extended-release corticosteroid injection indicated for osteoarthritis knee pain, and iovera°, a cryoanalgesia system that uses controlled cooling to temporarily block peripheral nerves and relieve pain.

Formerly known as Pacira Pharmaceuticals, the company adopted the Pacira BioSciences name to reflect its broader focus on innovative pain and regenerative-health therapies.